Molnupiravir was associated with a decreased the risk of hospitalization from Covid-19 by only 30%, compared to a reduction of almost 90% with Pfizer's PAXLOVID. The FDA advisory committee also limited its use in non-pregnant adults because of their concerns about the potential risk of mutations in human DNA.